HOLX at a glance
Hologic (HOLX, SEC CIK 859737) filed its latest 10-K annual report on November 18, 2025, a 10-Q quarterly report on January 29, 2026, an 8-K current report on April 7, 2026 and Form 4 insider filings as recently as April 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 27, 2025 (FY2025), Hologic (HOLX) reported revenue of $4.1 billion (up 1.7% from FY2024) and net income of $565.7 million. Diluted EPS was $2.49.
- As of March 31, 2026, 35 institutional investment managers tracked by SignalX reported holding Hologic (HOLX) shares worth $6.5 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.1B
- +1.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 35 funds
- $6.5B · +1 vs prior quarter
- Latest 8-K
- Apr 7, 2026
- Item 1.01 · Item 1.02 · Item 3.03 · Item 3.01 · Item 2.01 · Item 5.02 · Item 5.01 · Item 7.01 · Item 5.03
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 27, 2025
Business Overview
- Core business model: Developer and supplier of diagnostics, medical imaging, and surgical products focused on women’s health across four segments: Diagnostics, Breast Health, GYN Surgical, Skeletal Health
- New digital cytology platform Genius Digital Diagnostics System cleared by FDA in Jan 2024, combines AI with volumetric imaging for cervical cancer detection
- Strategic emphasis on expanding breast health portfolio by integrating Endomagnetics' wire-free localization and lymphatic tracing acquired in fiscal 2024
- Discontinuation planned for Skeletal Health segment’s Fluoroscan Insight FD mini C-arm system effective fiscal 2026
- Proposed acquisition by Blackstone and TPG at $76 per share plus up to $3 CVR, expected to close in H1 2026, contingent on stockholder and regulatory approvals
Management Discussion & Analysis
- Cash and cash equivalents $1,959.5M, down $200.7M YoY due to stock repurchases, Gynesonics acquisition ($321.5M), capex $137M, strategic investments $35M
- Operating cash flow $1,057.1M driven by net income $565.7M and $299.8M depreciation, offset by $141.6M deferred tax decrease
- Financing outflow $777.2M including $752.9M in stock repurchases and $28.5M debt repayments
- Debt $2.51B at FY25 end: $1.167B 2025 Term Loan, $942.9M 2029 Senior Notes (3.25% interest), $398.3M 2028 Senior Notes (4.625% interest)
- Board authorized $1.5B stock repurchase program; $937.5M remaining as of Sept 2025; repurchase activity restricted by merger agreement with Blackstone and TPG
Risk Factors
- Legal risk from ongoing governmental and regulatory investigations affecting potential litigation costs
- Macroeconomic exposure to increased Weighted Average Cost of Capital (WACC) impacting goodwill fair value, goodwill $3.6B at risk if markets deteriorate
- Operational risk of inventory obsolescence due to inaccurate demand forecasting for high-tech medical products
- Revenue disruption from embedded operating leases on instruments, impacting timing of recognition related to disposables sales
- Financial risk of significant indebtedness under 2025 Credit Agreement, 2028 and 2029 Senior Notes impacting liquidity and capital requirements
AI summary of the HOLX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Dec 27, 2025
Management Discussion & Analysis
- Revenue $1.05B total ($831.4M product + $216.4M service), product revenues up 1.7% YoY from $817.9M, driven by GYN Surgical (+8.0%) and Skeletal Health (+124.3%), partially offset by declines in Diagnostics (-0.8%) and Breast Health (-2.2%)
- Operating margin by segment: Diagnostics 33.9% vs 33.0% YoY (+0.9pp); Breast Health 27.3% vs 24.3% YoY (+3.0pp); GYN Surgical 22.4% vs 35.2% YoY (-12.8pp); Skeletal Health 10.5% vs -19.6% YoY (+30.1pp)
- Best performing segment: Skeletal Health revenue +69.0% to $26.7M with improved operating income $2.8M vs loss $3.1M prior year; Worst performing: GYN Surgical lowest margin and operating income fell 30.9% despite 8.7% revenue increase
- Cash and equivalents increased $208.5M to $2.17B; Operating cash flow $229.9M driven by net income $179.1M; Investing cash use $12.1M primarily capital expenditures and investments; Financing cash use $10.7M due to employee tax payments and equity plan proceeds
- Management highlights ongoing Brevera 9 Gauge Needle stop-ship and recall weighing on Breast Health product revenues; merger agreement with Blackstone and TPG expected closing H1 2026; expects sufficient liquidity over next 12 months; cautious on COVID testing volume decline and macroeconomic risks
Risk Factors
- Ongoing COVID-19 pandemic impact on supply chain and demand remains a key carried-forward risk
- Dependency on third-party suppliers could disrupt manufacturing and affect revenue continuity
- Regulatory scrutiny on diagnostic products could delay approvals or increase compliance costs
- Competition from new entrants and technologies threatens market share and pricing power
- Debt maturity schedule requires $600 million repayment by 2026, posing liquidity pressure
AI summary of the HOLX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- One CVR issued per Hologic share and certain equity awards outstanding immediately before merger effectiveness
- CVR holders may receive contingent future value tied to specified merger-related conditions
Item 1.02: Termination of a Material Definitive Agreement
- Merger closing triggered full repayment and termination of the amended credit facility, including liens, guarantees, and unused commitments
- $400 million of 4.625% 2028 Notes set for redemption at 100% plus accrued interest
Item 3.03: Material Modification to Rights of Security Holders
- Company common shares automatically cancelled at the merger’s Effective Time
- Former shareholders’ rights ended except entitlement to receive the Merger Consideration
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq trading suspended before April 7, 2026 following completion of the Merger
- Form 25 requested to delist all common shares and deregister them under Section 12(b)
Item 2.01: Completion of Acquisition or Disposition of Assets
- Acquisition completed; Hologic became a wholly owned subsidiary of Parent
- Common shareholders received $76.00 cash per share plus one contingent value right
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Merger completion triggered resignation of all nine pre-merger directors and board committees
- José (Joe) E. Almeida became the sole named incoming director
Item 5.01: Changes in Control of Registrant
- Control-change details incorporated from the filing’s Introductory Note and Items 2.01, 3.01, 3.03, 5.02 and 5.03
- Investor impact depends on those referenced sections, including governance, leadership and shareholder-rights changes
Item 7.01: Regulation FD Disclosure
- Merger officially closed on April 7, 2026, transitioning the transaction from announced to completed
- José (Joe) E. Almeida appointed Chief Executive Officer on the closing date
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Charter adopted at merger effective time, replacing prior governing document
- Bylaws amended and restated entirely using Merger Sub’s pre-closing form
Item EX-99.1: Item EX-99.1
- Blackstone and TPG completed Hologic’s acquisition, taking the company private and ending public-market access
- Stockholders receive $76 per share cash plus non-tradable CVR worth up to $3 per share
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stephen P. MacMillan retiring as CEO and Board Chairman after Blackstone-TPG acquisition closes
- Retirement contingent on merger completion under October 21, 2025 agreement
Item 8.01: Other Events
- All regulatory approvals received, removing a major condition to Hologic’s merger closing
- Merger expected to close April 7, 2026, subject to customary closing conditions
Item EX-99.1: Item EX-99.1
- CEO Steve MacMillan retiring upon expected April 7, 2026 close of Blackstone and TPG go-private transaction
- CEO succession remains unresolved until transaction closing, creating near-term leadership transition uncertainty
AI summaries of HOLX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HOLX
Don't miss the next HOLX filing
- Alerts as it files. A push when HOLX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HOLX, by share count.
- Ask anything. An AI agent that reads every HOLX filing and answers with sources.
HOLX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 1,146,829 | - |
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 160,565 | - |
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 159,339 | - |
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 768,639 | - |
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 151,071 | - |
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 152,529 | - |
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 123,801 | - |
| MACMILLAN STEPHEN P | D | Apr 7, 2026 | 118,877 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.0B | $4.1B |
| Gross Profit | - | $2.2B | $2.1B |
| Operating Income | - | $882.6M | $714.3M |
| Net Income | - | $789.5M | $565.7M |
| Gross Margin | - | 55.3% | 51.6% |
| Op. Margin | - | 21.9% | 17.4% |
| Net Margin | - | 19.6% | 13.8% |
| Balance Sheet | |||
| Total Assets | $9.1B | $9.2B | $9.0B |
| Equity | $5.0B | $5.1B | $5.0B |
| ROE | - | 15.4% | 11.2% |
| Per Share | |||
| EPS | - | $3.32 | $2.49 |
| Cash Flow | |||
| Operating CF | - | $1.3B | $1.1B |
| CapEx | - | $72.4M | $58.8M |
Source: XBRL data in Hologic (HOLX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate HOLX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q1 2026 | 35 | $6.55B |
| Q4 2025 | 34 | $6.45B |
| Q3 2025 | 37 | $6.29B |
| Q2 2025 | 37 | $6.05B |
| Q1 2025 | 31 | $4.54B |
| Q4 2024 | 29 | $4.57B |
| Q3 2024 | 26 | $2.48B |
- Millennium Management+2.15M (+61%)
- JPMorgan Chase & Co+1.62M (+96%)
- Goldman Sachs Group+1.32M (+131%)
- Morgan Stanley+1.21M (+51%)
- BlackRock+422.0K (+2%)
- Dimensional Fund Advisors−1.90M (-84%)
- Bank of America Corp−680.1K (-23%)
- AQR Capital Management−491.2K (-81%)
- Wells Fargo & Co−475.2K (-84%)
- Invesco Ltd−426.9K (-12%)
- Vanguard Group Inc−26.09M
- Renaissance Technologies LLC−1.32M
Source: 13F-HR filings on SEC EDGAR (aggregated from 229 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HOLX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Apr 30, 2026 | - | - | |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 9, 2026 | - | - | - |
| 8-K | Apr 7, 2026 | - | Analysis | - |
| 8-K | Apr 6, 2026 | - | Analysis | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
Related Health Care companies
- BFLY · Butterfly Network, Inc.X-Ray Apparatus & Tubes & Related Irradiation Apparatus
- GEHC · GE HealthCareX-Ray Apparatus & Tubes & Related Irradiation Apparatus
- NNOX · Nano-X Imaging Ltd.X-Ray Apparatus & Tubes & Related Irradiation Apparatus
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
HOLX SEC filings: frequently asked questions
Which institutions hold HOLX stock?
As of March 31, 2026, the largest Hologic (HOLX) holders among the 13F filers tracked by SignalX were BlackRock ($1.7 billion), Vanguard Capital Management LLC ($1.1 billion), State Street Corp ($755.2 million), Vanguard Portfolio Management LLC ($727.2 million), Millennium Management ($427.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HOLX's revenue in fiscal year 2025?
For the fiscal year ended September 27, 2025 (FY2025), Hologic (HOLX) reported revenue of $4.1 billion (up 1.7% from FY2024) and net income of $565.7 million. Diluted EPS was $2.49. The figures come from the XBRL data in the 10-K.
What are the main risks in HOLX's latest 10-K?
In the 10-K filed November 18, 2025, Hologic (HOLX) flagged: Legal risk from ongoing governmental and regulatory investigations affecting potential litigation costs. Macroeconomic exposure to increased Weighted Average Cost of Capital (WACC) impacting goodwill fair value, goodwill $3.6B at risk if markets deteriorate. (AI summary of the Risk Factors section.)
What did HOLX report in its latest 8-K?
Hologic (HOLX) filed an 8-K on April 7, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 3.03 (Material Modification to Rights of Security Holders), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 5.02 (Departure/Appointment of Directors or Principal Officers), Item 5.01 (Changes in Control of Registrant), Item 7.01 (Regulation FD Disclosure) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws). One CVR issued per Hologic share and certain equity awards outstanding immediately before merger effectiveness.
What are the latest HOLX SEC filings?
Hologic (HOLX) filed its latest 10-K annual report on November 18, 2025, a 10-Q quarterly report on January 29, 2026, an 8-K current report on April 7, 2026 and a Form 4 insider filing on April 9, 2026.
What is HOLX's SEC CIK number?
Hologic (HOLX)'s SEC Central Index Key (CIK) is 859737. EDGAR lists every HOLX filing under that number.
Ask anything about HOLX
The research agent reads HOLX's filings, financials, insider trades and 13F holders, then answers with sources.